Literature DB >> 26487272

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.

T Fischer1, F H Heidel1, P Arreba-Tutusaus1, T S Mack1, L Bullinger2,3, T M Schnöder1, A Polanetzki1, S Weinert4, A Ballaschk1, Z Wang3, A J Deshpande3,5, S A Armstrong3,6, K Döhner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26487272      PMCID： PMC4840097          DOI： 10.1038/leu.2015.292

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

Authors:  Florian Heidel; Fian K Solem; Frank Breitenbuecher; Daniel B Lipka; Stefan Kasper; M H Thiede; Christian Brandts; Hubert Serve; Johannes Roesel; Francis Giles; Eric Feldman; Gerhard Ehninger; Gary J Schiller; Stephen Nimer; Richard M Stone; Yanfeng Wang; Thomas Kindler; Pamela S Cohen; Christoph Huber; Thomas Fischer
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

Authors:  Derek L Stirewalt; Kenneth J Kopecky; Soheil Meshinchi; Julia H Engel; Era L Pogosova-Agadjanyan; Jeremy Linsley; Marilyn L Slovak; Cheryl L Willman; Jerald P Radich
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

3.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Authors:  Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah
Journal:  Nature       Date:  2012-04-15       Impact factor: 49.962

4.  Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Tamara Alpermann; Wolfgang Kern; Torsten Haferlach
Journal:  Genes Chromosomes Cancer       Date:  2012-06-04       Impact factor: 5.006

5.  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

Authors:  Sabine Kayser; Richard F Schlenk; Martina Correa Londono; Frank Breitenbuecher; Kerstin Wittke; Juan Du; Silja Groner; Daniela Späth; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Thomas Fischer; Konstanze Döhner
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

6.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

7.  The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.

Authors:  C Miething; S Feihl; C Mugler; R Grundler; N von Bubnoff; F Lordick; C Peschel; J Duyster
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

8.  Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.

Authors:  Frank Breitenbuecher; Susanne Schnittger; Rebekka Grundler; Boyka Markova; Birgit Carius; Alexandra Brecht; Justus Duyster; Torsten Haferlach; Christoph Huber; Thomas Fischer
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

9.  An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML.

Authors:  Lars Bullinger; Konstanze Döhner; Raphael Kranz; Christoph Stirner; Stefan Fröhling; Claudia Scholl; Young H Kim; Richard F Schlenk; Robert Tibshirani; Hartmut Döhner; Jonathan R Pollack
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

10.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245
View more
  19 in total

1.  Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.

Authors:  Mike Fischer; Ulf Schnetzke; Bärbel Spies-Weisshart; Mario Walther; Maximilian Fleischmann; Inken Hilgendorf; Andreas Hochhaus; Sebastian Scholl
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941

2.  Impact of FLT3-ITD length on prognosis of acute myeloid leukemia.

Authors:  Song-Bai Liu; Hao-Jie Dong; Xie-Bing Bao; Qiao-Cheng Qiu; Hong-Zhi Li; Hong-Jie Shen; Zi-Xuan Ding; Chao Wang; Xiao-Ling Chu; Jing-Qiu Yu; Tao Tao; Zheng Li; Xiao-Wen Tang; Su-Ning Chen; De-Pei Wu; Ling Li; Sheng-Li Xue
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

Review 3.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

4.  Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Authors:  Silvia Maifrede; Margaret Nieborowska-Skorska; Katherine Sullivan-Reed; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Bac Viet Le; Martyna Solecka; Zhaorui Lian; Elizaveta A Belyaeva; Alina Nersesyan; Marcin M Machnicki; Monika Toma; Nicolas Chatain; Malgorzata Rydzanicz; Huaqing Zhao; Jaroslav Jelinek; Katarzyna Piwocka; Tomasz Sliwinski; Tomasz Stoklosa; Rafal Ploski; Thomas Fischer; Stephen M Sykes; Steffen Koschmieder; Lars Bullinger; Peter Valent; Mariusz A Wasik; Jian Huang; Tomasz Skorski
Journal:  Blood       Date:  2018-05-21       Impact factor: 22.113

Review 5.  Combining Mass Spectrometry-Based Phosphoproteomics with a Network-Based Approach to Reveal FLT3-Dependent Mechanisms of Chemoresistance.

Authors:  Giusj Monia Pugliese; Sara Latini; Giorgia Massacci; Livia Perfetto; Francesca Sacco
Journal:  Proteomes       Date:  2021-04-27

6.  Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.

Authors:  Anne-Kathrin Garz; Saskia Wolf; Sonja Grath; Verena Gaidzik; Stefan Habringer; Binje Vick; Martina Rudelius; Christoph Ziegenhain; Sylvia Herold; Marie-Theresa Weickert; Martha Smets; Christian Peschel; Robert A J Oostendorp; Sebastian Bultmann; Irmela Jeremias; Christian Thiede; Konstanze Döhner; Ulrich Keller; Katharina S Götze
Journal:  Oncotarget       Date:  2017-10-16

7.  The target landscape of clinical kinase drugs.

Authors:  Susan Klaeger; Stephanie Heinzlmeir; Mathias Wilhelm; Harald Polzer; Binje Vick; Paul-Albert Koenig; Maria Reinecke; Benjamin Ruprecht; Svenja Petzoldt; Chen Meng; Jana Zecha; Katrin Reiter; Huichao Qiao; Dominic Helm; Heiner Koch; Melanie Schoof; Giulia Canevari; Elena Casale; Stefania Re Depaolini; Annette Feuchtinger; Zhixiang Wu; Tobias Schmidt; Lars Rueckert; Wilhelm Becker; Jan Huenges; Anne-Kathrin Garz; Bjoern-Oliver Gohlke; Daniel Paul Zolg; Gian Kayser; Tonu Vooder; Robert Preissner; Hannes Hahne; Neeme Tõnisson; Karl Kramer; Katharina Götze; Florian Bassermann; Judith Schlegl; Hans-Christian Ehrlich; Stephan Aiche; Axel Walch; Philipp A Greif; Sabine Schneider; Eduard Rudolf Felder; Juergen Ruland; Guillaume Médard; Irmela Jeremias; Karsten Spiekermann; Bernhard Kuster
Journal:  Science       Date:  2017-12-01       Impact factor: 47.728

8.  Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.

Authors:  D B Lipka; M-C Wagner; M Dziadosz; T Fischer
Journal:  Leukemia       Date:  2016-05-03       Impact factor: 11.528

9.  Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.

Authors:  Alissa Marhäll; Florian Heidel; Thomas Fischer; Lars Rönnstrand
Journal:  Ann Hematol       Date:  2018-01-25       Impact factor: 3.673

10.  Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.

Authors:  K Reiter; H Polzer; C Krupka; A Maiser; B Vick; M Rothenberg-Thurley; K H Metzeler; D Dörfel; H R Salih; G Jung; E Nößner; I Jeremias; W Hiddemann; H Leonhardt; K Spiekermann; M Subklewe; P A Greif
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.